Should the blood pressure target for all individuals with type 2 diabetes and hypertension be

Investigators from the Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure (DAPA-HF) will discuss the latest findings from the study during the 80th Virtual Scientific Sessions. Silvio E. Inzucchi, MD, will review the metabolic and safety aspects of DAPA-HF.

Ongoing data analyses from the New Insights from the Restoring Insulin Secretion (RISE) Study continue to shed light on important differences between adults and youth in the onset and progression of type 2 diabetes. A panel of RISE investigators, including RISE Steering Committee Chair Steven E. Kahn, MB, ChB, will discuss the latest findings at…

Glucagon-like peptide-1 (GLP-1) receptor agonists reduce the risk of myocardial infarction, stroke, and similar cardiovascular events, but questions remain about the mechanisms behind the cardioprotection the drugs provide. During a Virtual Scientific Sessions symposium, Daniel J. Drucker, MD, and two other researchers will address the question, How Do GLP-1 Receptor Agonists Provide Cardioprotection?

During a virtual presentation at the Scientific Sessions, Athena Philis-Tsimikas, MD, and Elbert Huang, MD, MPH, FACP, will debate the value of continuous glucose monitoring (CGM) in patients with type 2 diabetes. ADAMeetingNews.org spoke to Drs. Philis-Tsimikas and Huang for a preview of the debate.

Four experts will provide an update on lipid-lowering drugs during a two-hour virtual presentation at the Scientific Sessions. The session’s panelists include Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC; Jennifer G. Robinson, MD, MPH; and John R. Guyton, MD.

Detailed findings from the VERTIS-CV trial looking at the safety and efficacy of ertugliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, will be presented Tuesday, June 16, by a panel of trial investigators. Christopher P. Cannon, MD, a member of the VERTIS-CV trial Scientific Advisory Committee, will present cardiovascular and renal outcomes from the trial.

A panel of investigators, including Beena Akolkar, PhD, will present recent findings from the ongoing TEDDY Study during the Scientific Sessions. TEDDY is a multi-center study funded by the NIDDK designed to investigate the etiology of type 1 diabetes and identify environmental triggers of the disease.

Ongoing advances in the accuracy and affordability of continuous glucose monitoring technologies have led to a growing emphasis on time-in-range as a primary metric in pediatric diabetes. A panel of experts, including Daniel J. DeSalvo, MD, will review the growing evidence supporting time-in-range and discuss recommendations for incorporating the metric into clinical practice during the…

During a Friday afternoon symposium at the Scientific Sessions, a panel of experts will discuss the latest recommendations and research findings regarding treatment options for patients with common diabetes comorbidities. Panelists include George Bakris, MD, Silvio E. Inzucchi, MD, and Jesse Dawson, MD, BSc (Hons), FRCP, FESO.